KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 79 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $185,116 | -23.2% | 138,157 | +2.7% | 0.00% | – |
Q2 2023 | $240,907 | +59236.7% | 134,585 | +29.0% | 0.00% | -100.0% |
Q1 2023 | $406 | +20.8% | 104,291 | +5.6% | 0.00% | – |
Q4 2022 | $336 | -99.9% | 98,740 | -1.0% | 0.00% | -100.0% |
Q3 2022 | $545,000 | +32.3% | 99,742 | +9.1% | 0.00% | 0.0% |
Q2 2022 | $412,000 | -29.3% | 91,430 | +15.6% | 0.00% | 0.0% |
Q1 2022 | $583,000 | -4.3% | 79,123 | -16.5% | 0.00% | 0.0% |
Q4 2021 | $609,000 | +8.8% | 94,710 | -1.5% | 0.00% | 0.0% |
Q3 2021 | $560,000 | -56.8% | 96,191 | -23.5% | 0.00% | -50.0% |
Q2 2021 | $1,297,000 | +2.0% | 125,687 | +3.9% | 0.00% | 0.0% |
Q1 2021 | $1,272,000 | -34.1% | 120,927 | -3.0% | 0.00% | -33.3% |
Q4 2020 | $1,930,000 | +8.6% | 124,709 | +2.5% | 0.00% | 0.0% |
Q3 2020 | $1,777,000 | -33.1% | 121,708 | -13.3% | 0.00% | -25.0% |
Q2 2020 | $2,658,000 | +9.6% | 140,356 | +11.1% | 0.00% | -20.0% |
Q1 2020 | $2,426,000 | +2.3% | 126,277 | +2.1% | 0.01% | +25.0% |
Q4 2019 | $2,372,000 | +112.7% | 123,722 | +6.7% | 0.00% | +100.0% |
Q3 2019 | $1,115,000 | +61.1% | 115,903 | +0.4% | 0.00% | +100.0% |
Q2 2019 | $692,000 | -10.6% | 115,468 | -12.9% | 0.00% | 0.0% |
Q1 2019 | $774,000 | -11.9% | 132,550 | +41.3% | 0.00% | -50.0% |
Q4 2018 | $879,000 | +21.1% | 93,819 | +119.9% | 0.00% | +100.0% |
Q3 2018 | $726,000 | -5.7% | 42,656 | -5.9% | 0.00% | -50.0% |
Q2 2018 | $770,000 | +71.1% | 45,331 | +35.1% | 0.00% | +100.0% |
Q1 2018 | $450,000 | +43.8% | 33,560 | +3.0% | 0.00% | 0.0% |
Q4 2017 | $313,000 | -62.1% | 32,585 | -56.7% | 0.00% | -50.0% |
Q3 2017 | $826,000 | +22.0% | 75,207 | +0.5% | 0.00% | 0.0% |
Q2 2017 | $677,000 | -23.3% | 74,812 | +8.8% | 0.00% | 0.0% |
Q1 2017 | $883,000 | +45.0% | 68,787 | +6.1% | 0.00% | 0.0% |
Q4 2016 | $609,000 | -23.3% | 64,802 | -20.6% | 0.00% | 0.0% |
Q3 2016 | $794,000 | +83.4% | 81,580 | +26.6% | 0.00% | +100.0% |
Q2 2016 | $433,000 | +117.6% | 64,460 | +188.5% | 0.00% | 0.0% |
Q1 2016 | $199,000 | -32.5% | 22,341 | +0.4% | 0.00% | 0.0% |
Q4 2015 | $295,000 | +35.3% | 22,241 | +7.2% | 0.00% | 0.0% |
Q3 2015 | $218,000 | -58.9% | 20,746 | +6.3% | 0.00% | -50.0% |
Q2 2015 | $531,000 | +29.2% | 19,525 | +45.3% | 0.00% | +100.0% |
Q1 2015 | $411,000 | +4.1% | 13,440 | +27.2% | 0.00% | 0.0% |
Q4 2014 | $395,000 | +10.3% | 10,565 | +3.2% | 0.00% | 0.0% |
Q3 2014 | $358,000 | -26.9% | 10,240 | -2.7% | 0.00% | 0.0% |
Q2 2014 | $490,000 | – | 10,520 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,200,396 | $30,084,000 | 1.72% |
TFS CAPITAL LLC | 105,040 | $987,000 | 0.26% |
Tekla Capital Management LLC | 500,324 | $4,703,000 | 0.20% |
Piermont Capital Management Inc. | 51,080 | $480,000 | 0.11% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 55,793 | $524,000 | 0.09% |
Candriam S.C.A. | 390,000 | $3,666,000 | 0.08% |
Virtus ETF Advisers LLC | 27,446 | $258,000 | 0.08% |
SECOR Capital Advisors, LP | 66,484 | $625,000 | 0.08% |
Trexquant Investment LP | 29,007 | $273,000 | 0.04% |
PRELUDE CAPITAL MANAGEMENT, LLC | 32,196 | $303,000 | 0.04% |